A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer
Public ClinicalTrials.gov record NCT04075604. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Non-comparative Neoadjuvant Phase II Study in Patients With ER+/HER2- Breast Cancer >= 2 cm With Safety Run-in, Assessing Nivolumab + Palbociclib + Anastrozole
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A randomized multi-arm study evaluating the safety and efficacy of palbociclib and anastrozole with or without nivolumab in participants with ER+/HER2- breast cancer
Study identification
- NCT ID
- NCT04075604
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 23 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 17, 2019
- Primary completion
- Jul 26, 2021
- Completion
- Jul 26, 2021
- Last update posted
- Aug 9, 2022
2019 – 2021
United States locations
- U.S. sites
- 9
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0031 | Whittier | California | 90603 | — |
| University Cancer Blood Ctr | Athens | Georgia | 30607 | — |
| Northside Hospital,Inc.- Central Research Department | Atlanta | Georgia | 30342 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Local Institution - 0041 | Florham Park | New Jersey | 07932 | — |
| The Cancer Center At Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| MetroHealth Medical Center | Cleveland | Ohio | 44109 | — |
| Hematology-Oncology Associates Of Fredricksburg, Inc | Fredericksburg | Virginia | 22408 | — |
| Peninsula Cancer Institute | Newport News | Virginia | 23601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04075604, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 9, 2022 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04075604 live on ClinicalTrials.gov.